

Table 4: ART Regimens for Initial Treatment of Pregnant Adults With HIV-2 [a]			
Regimen			Rating
<i>Preferred</i>			
Tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC; Biktarvy)			A3
Tenofovir alafenamide/emtricitabine (TAF/FTC; Descovy) OR Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC; Truvada) OR Tenofovir disoproxil fumarate/lamivudine (TDF/3TC; multiple brands)	AND	Dolutegravir [b,c] (DTG; Tivicay)	A3
<i>Alternative</i>			
Tenofovir alafenamide/emtricitabine (TAF/FTC; Descovy) OR Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC; Truvada) OR Tenofovir disoproxil fumarate/lamivudine (TDF/3TC; multiple brands)	AND	Ritonavir-boosted darunavir twice daily (DRV/r; Prezista and Norvir) OR Raltegravir twice daily (RAL; Isentress)	B3
<p>Notes:</p> <p>a. Listed alphabetically; for specific details, see NYSDOH AI guideline Selecting an Initial ART Regimen > Specific Factors to Consider and Discuss With Patients and prescribing information.</p> <p>b. A single-tablet regimen of abacavir/lamivudine/dolutegravir is available but is not recommended as a preferred or alternative ART regimen. Abacavir is likely associated with cardiovascular disease (CVD) even among individuals with low-to-moderate risk for atherosclerotic CVD and should be avoided in an initial ART regimen. See NYSDOH AI guideline Selecting an Initial ART Regimen > Special Considerations for Comorbid Conditions > Cardiovascular risks.</p> <p>c. DTG has been shown to be safe throughout pregnancy [Zash, et al. 2022].</p>			

Reference

Zash R, Holmes LB, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo Study, Botswana. AIDS; 2022 Jul 29–Aug 2; Montreal, Canada. https://www.natap.org/2022/IAC/IAC_31.htm